186 related articles for article (PubMed ID: 22414379)
1. Clinical correlates of atypical femoral fracture.
Lo JC; Huang SY; Lee GA; Khandelwal S; Provus J; Ettinger B; Gonzalez JR; Hui RL; Grimsrud CD
Bone; 2012 Jul; 51(1):181-4. PubMed ID: 22414379
[TBL] [Abstract][Full Text] [Related]
2. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
Black DM; Geiger EJ; Eastell R; Vittinghoff E; Li BH; Ryan DS; Dell RM; Adams AL
N Engl J Med; 2020 Aug; 383(8):743-753. PubMed ID: 32813950
[TBL] [Abstract][Full Text] [Related]
3. Hip and Subtrochanteric or Femoral Shaft Fractures after Bisphosphonate Use in Korean Women, Using Korean National Sample Cohort.
Won SH; Ahn S; Ji E; Park JW; Kim JK; Lee YK
J Korean Med Sci; 2020 Jun; 35(25):e193. PubMed ID: 32597040
[TBL] [Abstract][Full Text] [Related]
4. Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy.
Chang ST; Tenforde AS; Grimsrud CD; O'Ryan FS; Gonzalez JR; Baer DM; Chandra M; Lo JC
Bone; 2012 Sep; 51(3):524-7. PubMed ID: 22634175
[TBL] [Abstract][Full Text] [Related]
5. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates.
Nieves JW; Cosman F
Curr Osteoporos Rep; 2010 Mar; 8(1):34-9. PubMed ID: 20425089
[TBL] [Abstract][Full Text] [Related]
6. Critical differences between subtrochanteric and diaphyseal atypical femoral fractures: analyses of 51 cases at a single institution in Korean population.
Cho YJ; Kang KC; Chun YS; Rhyu KH; Kim SJ; Jang TS
Arch Osteoporos; 2018 May; 13(1):53. PubMed ID: 29725835
[TBL] [Abstract][Full Text] [Related]
7. Trends in the incidence of atypical femoral fractures and bisphosphonate therapy.
Clout A; Narayanasamy N; Harris I
J Orthop Surg (Hong Kong); 2016 Apr; 24(1):36-40. PubMed ID: 27122510
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.
Park-Wyllie LY; Mamdani MM; Juurlink DN; Hawker GA; Gunraj N; Austin PC; Whelan DB; Weiler PJ; Laupacis A
JAMA; 2011 Feb; 305(8):783-9. PubMed ID: 21343577
[TBL] [Abstract][Full Text] [Related]
9. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.
Wang Z; Ward MM; Chan L; Bhattacharyya T
Osteoporos Int; 2014 Aug; 25(8):2109-16. PubMed ID: 24846316
[TBL] [Abstract][Full Text] [Related]
10. Are women with thicker cortices in the femoral shaft at higher risk of subtrochanteric/diaphyseal fractures? The study of osteoporotic fractures.
Napoli N; Jin J; Peters K; Wustrack R; Burch S; Chau A; Cauley J; Ensrud K; Kelly M; Black DM
J Clin Endocrinol Metab; 2012 Jul; 97(7):2414-22. PubMed ID: 22547423
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.
Black DM; Kelly MP; Genant HK; Palermo L; Eastell R; Bucci-Rechtweg C; Cauley J; Leung PC; Boonen S; Santora A; de Papp A; Bauer DC; ;
N Engl J Med; 2010 May; 362(19):1761-71. PubMed ID: 20335571
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic Fixation Can Be Cost-effective in Preventing a Contralateral Bisphosphonate-associated Femur Fracture.
Jiang SY; Kaufman DJ; Chien BY; Longoria M; Shachter R; Bishop JA
Clin Orthop Relat Res; 2019 Mar; 477(3):480-490. PubMed ID: 30394950
[TBL] [Abstract][Full Text] [Related]
13. Racial/ethnic differences in hip and diaphyseal femur fractures.
Lo JC; Zheng P; Grimsrud CD; Chandra M; Ettinger B; Budayr A; Lau G; Baur MM; Hui RL; Neugebauer R
Osteoporos Int; 2014 Sep; 25(9):2313-8. PubMed ID: 24964891
[TBL] [Abstract][Full Text] [Related]
14. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals.
Thompson RN; Phillips JR; McCauley SH; Elliott JR; Moran CG
J Bone Joint Surg Br; 2012 Mar; 94(3):385-90. PubMed ID: 22371548
[TBL] [Abstract][Full Text] [Related]
15. Retrospective review of patients with atypical bisphosphonate related proximal femoral fractures.
Phillips HK; Harrison SJ; Akrawi H; Sidhom SA
Injury; 2017 Jun; 48(6):1159-1164. PubMed ID: 28410753
[TBL] [Abstract][Full Text] [Related]
16. Symptomatic atypical femoral fractures are related to underlying hip geometry.
Taormina DP; Marcano AI; Karia R; Egol KA; Tejwani NC
Bone; 2014 Jun; 63():1-6. PubMed ID: 24565751
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: sensitivity and trim and fill studies.
Liu J; Zhang HX; Lu XX; Hu JJ; Deng LF
Genet Test Mol Biomarkers; 2014 Feb; 18(2):117-22. PubMed ID: 24205872
[TBL] [Abstract][Full Text] [Related]
18. [Is SSBT associated with atypical femoral fracture? SSBT isn't associated with atypical femoral fracture].
Soen S
Clin Calcium; 2012 Jun; 22(6):919-22. PubMed ID: 22653034
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates and the risk of atypical femur fractures.
Black DM; Condra K; Adams AL; Eastell R
Bone; 2022 Mar; 156():116297. PubMed ID: 34920168
[TBL] [Abstract][Full Text] [Related]
20. Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry.
Hagen JE; Miller AN; Ott SM; Gardner M; Morshed S; Jeray K; Alton TB; Ren D; Abblitt WP; Krieg JC
J Bone Joint Surg Am; 2014 Nov; 96(22):1905-9. PubMed ID: 25410509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
